$3.74
3.31% today
NYSE, Feb 05, 04:24 pm CET
ISIN
US03237H1014
Symbol
AMLX
Sector
Industry

Amylyx Pharmaceuticals Stock price

$3.62
-0.30 7.65% 1M
+1.65 83.76% 6M
-0.16 4.23% YTD
-11.68 76.34% 1Y
-18.90 83.93% 3Y
-14.45 79.97% 5Y
-14.45 79.97% 10Y
NYSE, Closing price Tue, Feb 04 2025
+0.20 5.85%
ISIN
US03237H1014
Symbol
AMLX
Sector
Industry

Key metrics

Market capitalization $248.14m
Enterprise Value $16.31m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.08
P/S ratio (TTM) P/S ratio 1.26
P/B ratio (TTM) P/B ratio 1.26
Revenue growth (TTM) Revenue growth -33.22%
Revenue (TTM) Revenue $196.49m
EBIT (operating result TTM) EBIT $-213.09m
Free Cash Flow (TTM) Free Cash Flow $-95.58m
Cash position $234.40m
EPS (TTM) EPS $-3.82
P/E forward negative
P/S forward 2.82
EV/Sales forward 0.19
Short interest 3.12%
Show more

Is Amylyx Pharmaceuticals a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Amylyx Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Amylyx Pharmaceuticals forecast:

3x Buy
75%
1x Hold
25%

Analyst Opinions

4 Analysts have issued a Amylyx Pharmaceuticals forecast:

Buy
75%
Hold
25%

Financial data from Amylyx Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
196 196
33% 33%
100%
- Direct Costs 135 135
580% 580%
69%
61 61
78% 78%
31%
- Selling and Administrative Expenses 148 148
16% 16%
76%
- Research and Development Expense 125 125
19% 19%
64%
-212 -212
3,037% 3,037%
-108%
- Depreciation and Amortization 1.05 1.05
8% 8%
1%
EBIT (Operating Income) EBIT -213 -213
2,658% 2,658%
-108%
Net Profit -259 -259
14,202% 14,202%
-132%

In millions USD.

Don't miss a Thing! We will send you all news about Amylyx Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amylyx Pharmaceuticals Stock News

Neutral
Business Wire
15 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of ALS.
Neutral
Business Wire
26 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an underwritten public offering of 17,142,857 shares of its common stock at a public offering price of $3.50 per share. All of the shares are being offered by Amylyx. In addition, Amylyx has granted the underwriter a 30-day option to purchase up to an additio...
Neutral
Business Wire
27 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares are being offered by Amylyx. In addition, Amylyx intends to grant the underwriter a 30-day option to purchase additional shares of its common stock in an amount up to 15% ...
More Amylyx Pharmaceuticals News

Company Profile

Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in the provision of disease-modifying solutions for neurodegenerative diseases. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Head office United States
CEO Josh Klee
Employees 384
Founded 2013
Website www.amylyx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today